China
Africa
Explore chapters and articles related to this topic
Drugs Affecting the Central Nervous System
Published in Radhwan Nidal Al-Zidan, Drugs in Pregnancy, 2020
Risk Summary: Although Buspirone has been assigned with the letter (B), according to the FDA categorization, but it should be used with caution because no human data is available and the reproduction studies in animals have shown low risk.
Pharmacological Management of Huntington’s Disease
Published in Sahab Uddin, Rashid Mamunur, Advances in Neuropharmacology, 2020
Sonia Sharma, Sushant Sharma, Shallina Gupta
Three studies documented the management of aggressive and irritability behavior by buspirone at the dose range 20–60 mg/day (Bhandary and Masand, 1997; Byrne et al., 1994; Findling, 1993). Caution is advised during coadministration with MAOIs, CYP3A4, phenytoin, carbamazepine, dexamethasone, and so on. Dizziness, headache, nausea, and lightheadedness are the main side effects of buspirone drug.
Treatment of Psychological Disorders
Published in Mohamed Ahmed Abd El-Hay, Understanding Psychology for Medicine and Nursing, 2019
Buspirone is a non-benzodiazepine, azapirone derivative. It is a 5-HT1A partial agonist and a selective dopamine auto receptor antagonist. It also inhibits the spontaneous firing of 5-HT neurons. It does not seem to act on the benzodiazepine receptors. It has no sedative, anticonvulsant or muscle-relaxant properties. It is administered in a dose of 15–30 mg/day, in a thrice daily schedule due to its short half-life. As it has a slower and more gradual onset of action, it usually takes about two weeks before its anti-anxiety effects are evident. Buspirone is preferable in treatment of generalized anxiety disorders, but it is not useful in treatment of panic disorder. The common side effects include dizziness, headache, light-headedness, and diarrhea.
Beneficial effects of atypical antipsychotics on object recognition deficits after adolescent toluene exposure in mice: involvement of 5-HT1A receptors
Published in The American Journal of Drug and Alcohol Abuse, 2022
Mei-Yi Lee, Chung-Pin Hsieh, Ming-Huan Chan, Hwei-Hsien Chen
To further elucidate whether activation of 5-HT1A receptors is beneficial to the cognitive deficits induced by adolescent toluene exposure, the effects of a 5-HT1A receptor partial agonist buspirone were examined. Buspirone is primarily used to treat anxiety disorders, particularly generalized anxiety disorder. While buspirone did not dramatically improve cognitive dysfunction in patients with schizophrenia (34,35), possible beneficial effects from its administration have been suggested. It has been reported that acute treatment of buspirone counteracts the deficit of temporal order recognition memory induced by MK-801 (36). The present study showed that buspirone effectively reversed the toluene-induced recognition deficits and the effect was blocked by WAY-100635, supporting that activation of 5-HT1A receptors is a useful strategy to improve cognitive deficits after adolescent toluene exposure.
Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management
Published in Expert Opinion on Drug Safety, 2022
Joan Winter, Kimberly Curtis, Bo Hu, Anita H. Clayton
Buspirone has been proposed as an adjunctive agent to improve TESD. However, evidence in the form of randomized-controlled studies remains scarce. Post hoc analysis of a placebo-controlled trial by Landen et al demonstrated that SSRI non-responder MDD patients who were given flexible dosing of adjunctive buspirone (20-60 mg/day) for MDD saw improvements in sexual functioning as assessed by a clinician interview compared to patients randomized to adjunctive placebo[121]. It should be noted the primary endpoint of the study (depressive symptoms) was not met, and the authors suggest that buspirone’s mechanism of alleviating TESD may be independent of its antidepressant effect. As reported in the Michelson et al study mentioned prior, 57 euthymic fluoxetine-treated women with TESD randomized to augmentation with buspirone 20 mg/day, amantadine 50 mg/day or placebo indicated some subjective benefit, but differences were not statistically significant[107]. The dose of buspirone used in this study (10 mg twice daily) was likely inadequate given the doses in the Landen study above.
Mirtazapine decreased induction and expression of cocaine + nicotine-induced locomotor sensitisation in rats
Published in The World Journal of Biological Psychiatry, 2020
Susana Barbosa Méndez, Alberto Salazar-Juárez
Buspirone has an effect mainly on 5-HT1A receptors and D2-4 receptors (Khan and Haleem 2006; Bergman et al. 2013; Celada et al. 2013), while verenicline has primarily an impact on α4β2 and α7 nicotinic cholinergic receptors (Faessel et al. 2010; Maloku et al. 2011; Lange-Asschenfeldt et al. 2016). Studies that have evaluated the efficacy of modulation of dopaminergic or cholinergic receptors on the cocaine- or nicotine-behavioural effects have generated inconsistent results (Carrão et al. 2007; Nakamura et al. 2007; Plebani et al. 2012; Winhusen et al. 2012). Some pre-clinical and clinical studies indicate that administration of buspirone reduces cocaine behavioural effects (Winhusen et al. 2012, 2014; Langleben, 2014), but it does not alter behavioural responses to nicotine (Carrão et al. 2007). Alternatively, verenicline alters the reinforcing effect of nicotine (Jorenby et al. 2006; Nakamura et al. 2007; Tsai et al. 2007) but does not alter cocaine-reinforcing effects (Poling et al. 2010; Plebani et al. 2012).